Seroprevalence of Hepatitis B Surface Antigen and Liver Function Tests among Adolescents in Abakaliki, South Eastern Nigeria

10.5580/1726 ◽  
2010 ◽  
Vol 6 (2) ◽  
2015 ◽  
Vol 3 (1) ◽  
Author(s):  
Navid Sarakhs Asbaghi ◽  
Kazem Ghahreman Zadeh ◽  
Taher Faraj Zadeh ◽  
Javid Lotfi Attari ◽  
Zahra Javan Masoomi ◽  
...  

2016 ◽  
Vol 144 (12) ◽  
pp. 2648-2653 ◽  
Author(s):  
M. R. H. ROUSHAN ◽  
M. MOHAMMADPOUR ◽  
M. BAIANY ◽  
S. SOLEIMANI ◽  
A. BIJANI

SUMMARYTo determine the time to appearance of antibody against hepatitis B surface antigen (anti-HBs) after clearance of hepatitis B surface antigen (HBsAg) in chronically infected individuals, we followed up 3963 cases with positive antibody against hepatitis B e antigen (anti-HBe) from 1991 to 2014. Of these, 101 (67 males, 34 females) lost HBsAg. These serocleared cases were checked every 6-month interval regarding HBsAg, anti-HBs, liver function tests, and liver sonography. Hepatitis B virus DNA was assessed at the time of seroclearance or the appearance of anti-HBs. The mean age of these patients at entry to this study was 34·4 ± 13 years. The mean follow-up duration until seroclearance of HBsAg was 6·6 ± 4·3 years. After the mean follow-up of 43·7 ± 45 months, anti-HBs appeared in 64 (63·4%) cases. The cumulative probabilities of anti-HBs appearance for 2, 5 and 10 years were 24·3%, 58% and 78·2%, respectively. The appearance of anti-HBs was associated with age ⩾35 years and seroclearance of HBsAg (hazard ratio 1·96, 95% confidence interval 1·32–3·38,P= 0·016) but not with sex. The results show that anti-HBs may develop in 78·2% of cases within 10 years of HBsAg clearance. Age ⩾35 years at HBsAg loss was associated with earlier development of anti-HBs.


2015 ◽  
Vol 66 ◽  
pp. 90-94
Author(s):  
Celia Jackson ◽  
David J. Bell ◽  
Rory N. Gunson

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xiangxi Zhou ◽  
Fan Zhang ◽  
Yongping Ao ◽  
Chunli Lu ◽  
Tingting Li ◽  
...  

Abstract Background The aim of this study was to provide recommendations for reducing the impact of hepatitis B infection on patients with chronic hepatitis B by describing their experiences during the diagnosis process. Methods We conducted face-to-face interviews with 50 hepatitis B patients recruited by convenient sampling from an infectious diseases department of a teaching hospital in Chongqing, China from July to August 2019. Thematic analysis framework included interviewees’ social demographic characteristics, diagnosis approach, signs and symptoms before diagnosis, feelings after diagnosis, and doctor’s instructions. Results Most patients first detected hepatitis B through various types of physical examinations when the patients were asymptomatic or had only mild symptoms. Most patients were shocked, scared, or overwhelmed when they were diagnosed with hepatitis B. They were able to remember the doctor’s instructions about maintaining a healthy lifestyle, but not impressed by the doctor’s advice about regular follow-up liver function tests. The lack of regular follow-up has caused irreversible damage to some patients. Conclusions Most patients are passively diagnosed with hepatitis B due to their lack of awareness on active hepatitis B prevention. Patients need professional mental health care to overcome the negative emotions that following the diagnosis. Physicians’ instruction should emphasize the importance of regular follow-up liver function tests in addition to a healthy lifestyle.


2013 ◽  
Vol 36 (6) ◽  
pp. 422-428 ◽  
Author(s):  
Ioannis S. Elefsiniotis ◽  
Konstantinos Tsoumakas ◽  
Maria Kapritsou ◽  
Ioanna Magaziotou ◽  
Angeliki Derdemezi ◽  
...  

HIV ◽  
2020 ◽  
pp. 55-66
Author(s):  
Jessica A. Meisner ◽  
Mamta K. Jain

This chapter reviews the evaluation and management of a patient with HIV and hepatitis B virus (HBV) co-infection who has an acute rise in liver function tests (LFTs) after a change in his HIV regimen. Abnormal LFTs in a patient with HIV require a thorough workup, including review of medications, history, laboratory evaluation, and often an ultrasound. It describes the reasoning for being placed on active agents for both HIV and HBV. It recommends the use of a tenofovir-containing backbone in antiretroviral therapy (ART) and avoidance of lamivudine monotherapy. A change in ART that does not cover HBV could precipitate HBV rebound and a rise in LFTs.


Sign in / Sign up

Export Citation Format

Share Document